These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37893058)

  • 1. Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells.
    Sarsons CD; Gilham D; Tsujikawa LM; Wasiak S; Fu L; Rakai BD; Stotz SC; Carestia A; Sweeney M; Kulikowski E
    Biomedicines; 2023 Sep; 11(10):. PubMed ID: 37893058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells.
    Campbell AE; Oliva J; Yates MP; Zhong JW; Shadle SC; Snider L; Singh N; Tai S; Hiramuki Y; Tawil R; van der Maarel SM; Tapscott SJ; Sverdrup FM
    Skelet Muscle; 2017 Sep; 7(1):16. PubMed ID: 28870238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p38
    Rojas LA; Valentine E; Accorsi A; Maglio J; Shen N; Robertson A; Kazmirski S; Rahl P; Tawil R; Cadavid D; Thompson LA; Ronco L; Chang AN; Cacace AM; Wallace O
    J Pharmacol Exp Ther; 2020 Sep; 374(3):489-498. PubMed ID: 32576599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MATR3 is an endogenous inhibitor of DUX4 in FSHD muscular dystrophy.
    Runfola V; Giambruno R; Caronni C; Pannese M; Andolfo A; Gabellini D
    Cell Rep; 2023 Sep; 42(9):113120. PubMed ID: 37703175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression during normal and FSHD myogenesis.
    Tsumagari K; Chang SC; Lacey M; Baribault C; Chittur SV; Sowden J; Tawil R; Crawford GE; Ehrlich M
    BMC Med Genomics; 2011 Sep; 4():67. PubMed ID: 21951698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.
    van den Heuvel A; Mahfouz A; Kloet SL; Balog J; van Engelen BGM; Tawil R; Tapscott SJ; van der Maarel SM
    Hum Mol Genet; 2019 Apr; 28(7):1064-1075. PubMed ID: 30445587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy.
    Mariot V; Joubert R; Marsollier AC; Hourdé C; Voit T; Dumonceaux J
    Mol Ther Nucleic Acids; 2020 Dec; 22():1191-1199. PubMed ID: 33312755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-nucleus RNA-seq identifies divergent populations of FSHD2 myotube nuclei.
    Jiang S; Williams K; Kong X; Zeng W; Nguyen NV; Ma X; Tawil R; Yokomori K; Mortazavi A
    PLoS Genet; 2020 May; 16(5):e1008754. PubMed ID: 32365093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy.
    Jagannathan S
    Biochim Biophys Acta Mol Basis Dis; 2022 May; 1868(5):166367. PubMed ID: 35158020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
    Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
    Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.
    Banerji CRS; Panamarova M; Hebaishi H; White RB; Relaix F; Severini S; Zammit PS
    Nat Commun; 2017 Dec; 8(1):2152. PubMed ID: 29255294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of
    Duranti E; Villa C
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling Serum Antibodies Against Muscle Antigens in Facioscapulohumeral Muscular Dystrophy Finds No Disease-Specific Autoantibodies.
    Greco A; Straasheijm KR; Mul K; van den Heuvel A; van der Maarel SM; Joosten LAB; van Engelen BGM; Pruijn GJM
    J Neuromuscul Dis; 2021; 8(5):801-814. PubMed ID: 34024774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative proteomics reveals key roles for post-transcriptional gene regulation in the molecular pathology of facioscapulohumeral muscular dystrophy.
    Jagannathan S; Ogata Y; Gafken PR; Tapscott SJ; Bradley RK
    Elife; 2019 Jan; 8():. PubMed ID: 30644821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways.
    Rickard AM; Petek LM; Miller DG
    Hum Mol Genet; 2015 Oct; 24(20):5901-14. PubMed ID: 26246499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
    Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
    Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?
    Tassin A; Laoudj-Chenivesse D; Vanderplanck C; Barro M; Charron S; Ansseau E; Chen YW; Mercier J; Coppée F; Belayew A
    J Cell Mol Med; 2013 Jan; 17(1):76-89. PubMed ID: 23206257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct interplay between two candidate genes in FSHD muscular dystrophy.
    Ferri G; Huichalaf CH; Caccia R; Gabellini D
    Hum Mol Genet; 2015 Mar; 24(5):1256-66. PubMed ID: 25326393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells.
    Jagannathan S; Shadle SC; Resnick R; Snider L; Tawil RN; van der Maarel SM; Bradley RK; Tapscott SJ
    Hum Mol Genet; 2016 Oct; 25(20):4419-4431. PubMed ID: 28171552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy.
    Moyle LA; Blanc E; Jaka O; Prueller J; Banerji CR; Tedesco FS; Harridge SD; Knight RD; Zammit PS
    Elife; 2016 Nov; 5():. PubMed ID: 27841748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.